SPI
17.300,81
PKT
+82,32
PKT
+0,48
%
Werbung
Analysen zu SPI-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 23.11.12 | Clariant buy | UBS AG | |
| 23.11.12 | ARYZTA buy | UBS AG | |
| 23.11.12 | Kudelski sell | UBS AG | |
| 23.11.12 | EFG International buy | UBS AG | |
| 23.11.12 | Sonova kaufen | Fuchsbriefe | |
| 23.11.12 | ABB (Asea Brown Boveri) outperform | Sanford C. Bernstein and Co., Inc. | |
| 22.11.12 | Zurich Insurance neutral | Credit Suisse Group | |
| 22.11.12 | Zurich Insurance neutral | J.P. Morgan Cazenove | |
| 22.11.12 | Holcim buy | UBS AG | |
| 22.11.12 | Holcim buy | UBS AG | |
| 22.11.12 | Swiss Life buy | UBS AG | |
| 22.11.12 | Holcim hold | Vontobel Research | |
| 22.11.12 | SHL Telemedicine buy | Vontobel Research | |
| 22.11.12 | Basilea Pharmaceutica hold | Vontobel Research | |
| 22.11.12 | Autoneum hold | Vontobel Research | |
| 21.11.12 | Swatch (I) buy | Deutsche Bank AG | |
| 21.11.12 | UBS overweight | Morgan Stanley | |
| 21.11.12 | Givaudan overweight | J.P. Morgan Cazenove | |
| 21.11.12 | Novartis reduce | Vontobel Research | |
| 21.11.12 | Swiss Prime Site buy | Sarasin Research | |
| 21.11.12 | Swiss Prime Site hold | Vontobel Research | |
| 21.11.12 | DKSH hold | Vontobel Research | |
| 20.11.12 | Novartis outperform | Exane-BNP Paribas SA | |
| 20.11.12 | UBS neutral | Exane-BNP Paribas SA | |
| 20.11.12 | UBS outperform | Exane-BNP Paribas SA | |
| 20.11.12 | Holcim buy | Société Générale Group S.A. (SG) | |
| 20.11.12 | Novartis buy | Sarasin Research | |
| 20.11.12 | Peach Property Group buy | SRC Research GmbH | |
| 20.11.12 | UBS neutral | Sarasin Research | |
| 20.11.12 | OC Oerlikon buy | Vontobel Research | |
| 20.11.12 | UBS hold | Vontobel Research | |
| 20.11.12 | UBS halten | Norddeutsche Landesbank (Nord/LB) | |
| 19.11.12 | UBS halten | Norddeutsche Landesbank (Nord/LB) | |
| 19.11.12 | UBS buy | Sarasin Research | |
| 19.11.12 | Clariant neutral | HSBC | |
| 19.11.12 | Zurich Insurance halten | Independent Research GmbH | |
| 19.11.12 | Avolta (ex Dufry) outperform | Exane-BNP Paribas SA | |
| 16.11.12 | Zurich Insurance neutral | HSBC | |
| 16.11.12 | Givaudan outperform | Exane-BNP Paribas SA | |
| 16.11.12 | Novartis outperform | Exane-BNP Paribas SA |